Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v40-FR Version v36-FR
Language French French
Date Updated 2021-11-03 2020-02-13
Drug Identification Number 02243676 02243676
Brand name RECOMBIVAX HB -(PRESERVATIVE FREE) RECOMBIVAX HB -(PRESERVATIVE FREE)
Common or Proper name (hepatitis B vaccine [recombinant]) (hepatitis B vaccine [recombinant])
Company Name MERCK CANADA INC MERCK CANADA INC
Ingredients HEPATITIS B SURFACE ANTIGEN HEPATITIS B SURFACE ANTIGEN
Strength(s) 10MCG 10MCG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 10MCG/1ML 10X1DOSE VIAL 10MCG/1ML 10X1DOSE VIAL
ATC code J07BC J07BC
ATC description VIRAL VACCINES VIRAL VACCINES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2017-08-01 2017-08-01
Actual start date 2017-08-04 2017-08-04
Estimated end date 2022-06-30 2021-03-01
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Format 1DOSE VIAL remains available. / Le format 1DOSE VIAL est encore disponible. Recombivax (Adult presentation): Anticipated end date of the shortage - March 2021 (tbc).
Health Canada comments